Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies

NCT06561243 is registered in ClinicalTrials.gov with University Hospital, Caen as lead sponsor.

NCT NCT06561243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06561243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies
Lead sponsor
University Hospital, Caen
Phase
Observational
Overall status
Active, not recruiting
Start date
July 25, 2024
Completion date
October 30, 2024
Enrollment
15,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

btk inhibitors, cardiovascular diseases, chronic b-cell malignancies